Company / R&D per Share
BioLife Solutions, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.16
FY2025
5-year range
$0.10 / $0.31
FY2021-FY2025
Trend
+50.8%
vs FY2024
Sector context
#98 of 103
Health Care
What the data says
Among 103 Health Care companies, BioLife Solutions, Inc. is in the bottom 5% for r&d per share. R&D per Share returned to growth in FY2025 after 3 years of decline, reaching $0.16.
Based on SEC 10-K filings.
0.16 in FY2025 with a 5-year CAGR of -8.8%.
Improved from $0.13 to $0.16 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -8.2%
- 5-Year CAGR
- -8.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 103This company $0.16 Sector average $2.13
▼
-92.7% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 50.8% year-over-year.
- Ranks #98 out of 103 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.16 | +50.8% |
| FY2024 | $0.10 | -18.2% |
| FY2023 | $0.13 | -37.3% |
| FY2022 | $0.20 | -34.4% |
| FY2021 | $0.31 | +24.8% |
| FY2020 | $0.25 | +51.2% |
| FY2019 | $0.16 | +255.2% |
| FY2018 | $0.05 | -50.6% |
| FY2017 | $0.09 | -43.1% |
| FY2016 | $0.16 | +42.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026